^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD79b-targeted antibody-drug conjugate

    Related drugs:
    Apply
    Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) (NCT04833114)
    Phase 3
    GWT-TUD GmbH
    Active, not recruiting
    Last update posted :
    02/18/2025
    Initiation :
    04/30/2021
    Primary completion :
    12/31/2026
    Completion :
    12/31/2027
    BCL2 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement • CD20 negative
    |
    carboplatin • Rituxan (rituximab) • ifosfamide • etoposide IV • Polivy (polatuzumab vedotin-piiq)
    An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma (SKYGLO) (NCT06047080)
    Phase 3
    Hoffmann-La Roche
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    09/18/2023
    Primary completion :
    06/01/2026
    Completion :
    02/28/2029
    CD20
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)
    Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT04665765)
    Phase 2
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    02/17/2025
    Initiation :
    01/18/2021
    Primary completion :
    07/26/2022
    Completion :
    07/08/2025
    CD20
    |
    carboplatin • Rituxan (rituximab) • cyclophosphamide • ifosfamide • etoposide IV • Truxima (rituximab-abbs) • Polivy (polatuzumab vedotin-piiq) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar) • cyclophosphamide intravenous
    A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (SUNMO) (NCT05171647)
    Phase 3
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    02/14/2025
    Initiation :
    04/25/2022
    Primary completion :
    05/30/2025
    Completion :
    02/28/2027
    CD20 • CD4
    |
    gemcitabine • Rituxan (rituximab) • oxaliplatin • Actemra IV (tocilizumab) • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
    Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT06015880)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    01/30/2025
    Initiation :
    05/20/2024
    Primary completion :
    06/29/2026
    Completion :
    06/29/2026
    IFNG • CD79B • CD4
    |
    CD79B expression
    |
    lenalidomide • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
    A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL (NCT05615636)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    06/10/2024
    Initiation :
    04/28/2023
    Primary completion :
    08/19/2025
    Completion :
    08/19/2027
    CD20
    |
    lenalidomide • Monjuvi (tafasitamab-cxix) • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
    Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (GO40554) (NCT03677154)
    Phase 1/2
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    05/31/2024
    Initiation :
    05/23/2019
    Primary completion :
    08/03/2025
    Completion :
    08/03/2025
    CD20
    |
    Actemra IV (tocilizumab) • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
    A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL) (BO42203) (NCT04790903)
    Phase 1
    Hoffmann-La Roche
    Completed
    Last update posted :
    05/30/2024
    Initiation :
    07/02/2021
    Primary completion :
    05/21/2024
    Completion :
    05/21/2024
    BCL2 • CD20
    |
    CD20 positive
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq) • cyclophosphamide intravenous
    Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma (NCT04231877)
    Phase 1
    University of Washington
    Suspended
    Last update posted :
    04/25/2024
    Initiation :
    10/27/2020
    Primary completion :
    12/01/2026
    Completion :
    12/01/2031
    ALK • BCL2 • BCL6
    |
    BCL6 translocation
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • prednisone • daunorubicin • Truxima (rituximab-abbs) • Polivy (polatuzumab vedotin-piiq) • Riabni (rituximab-arrx) • Neupogen (filgrastim) • cyclophosphamide intravenous
    A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL (NCT04594798)
    Phase 2
    University of Rochester
    Recruiting
    Last update posted :
    04/16/2024
    Initiation :
    09/20/2021
    Primary completion :
    07/31/2024
    Completion :
    07/31/2024
    MYC • BCL2 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq) • cyclophosphamide intravenous
    A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma (POLARIX) (NCT03274492)
    Phase 3
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    04/11/2024
    Initiation :
    11/16/2017
    Primary completion :
    06/27/2024
    Completion :
    06/27/2024
    ALK • BCL2 • CD20 • BCL6
    |
    ALK positive • CD20 positive • BCL6 rearrangement
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Polivy (polatuzumab vedotin-piiq) • cyclophosphamide intravenous
    A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab as a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma (PORTAL) (NCT06071871)
    Phase 2
    University College, London
    Not yet recruiting
    Last update posted :
    04/01/2024
    Initiation :
    04/30/2024
    Primary completion :
    01/31/2027
    Completion :
    07/31/2028
    MYC • BCL2 • CD20 • BCL6
    |
    CD20 positive
    |
    Gazyva (obinutuzumab) • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)
    Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma (NCT04479267)
    Phase 2
    Barbara Ann Karmanos Cancer Institute
    Recruiting
    Last update posted :
    03/20/2024
    Initiation :
    08/21/2020
    Primary completion :
    11/15/2025
    Completion :
    11/15/2026
    MYC • BCL2 • BCL6
    |
    MYC overexpression • MYC expression • BCL6 rearrangement • BCL2 rearrangement
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Truxima (rituximab-abbs) • Polivy (polatuzumab vedotin-piiq) • Riabni (rituximab-arrx) • cyclophosphamide intravenous • methylprednisolone sodium succinate • prednisolone
    A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma (NCT05800366)
    Phase 2
    Jennifer Crombie, MD
    Recruiting
    Last update posted :
    02/23/2024
    Initiation :
    04/06/2023
    Primary completion :
    09/15/2026
    Completion :
    09/15/2029
    ALK • BCL2 • CD20 • BCL6
    |
    ALK positive • CD20 positive • MYC translocation
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)
    A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma (POLAR BEAR) (NCT04332822)
    Phase 3
    Nordic Lymphoma Group
    Recruiting
    Last update posted :
    02/13/2024
    Initiation :
    08/19/2020
    Primary completion :
    12/28/2025
    Completion :
    12/28/2028
    MYC • BCL2
    |
    MYC rearrangement + BCL2 rearrangement • MYC rearrangement • BCL2 rearrangement
    |
    doxorubicin hydrochloride • cyclophosphamide • Polivy (polatuzumab vedotin-piiq)
    A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma (GO40515) (NCT03677141)
    Phase 1/2
    Hoffmann-La Roche
    Completed
    Last update posted :
    02/06/2024
    Initiation :
    03/08/2019
    Primary completion :
    10/12/2023
    Completion :
    10/12/2023
    CD20
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Actemra IV (tocilizumab) • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb) • cyclophosphamide intravenous
    Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD) (NCT06040320)
    Phase 1/2
    Washington University School of Medicine
    Recruiting
    Last update posted :
    01/15/2024
    Initiation :
    10/04/2023
    Primary completion :
    05/31/2026
    Completion :
    05/31/2031
    CD20
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Polivy (polatuzumab vedotin-piiq)
    Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (NCT04659044)
    Phase 2
    Academic and Community Cancer Research United
    Active, not recruiting
    Last update posted :
    01/08/2024
    Initiation :
    04/01/2021
    Primary completion :
    04/04/2027
    Completion :
    04/01/2029
    CCND1
    |
    Chr t(11;14)
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • Truxima (rituximab-abbs) • Rituxan Hycela (rituximab/hyaluronidase) • Polivy (polatuzumab vedotin-piiq) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar)
    Parsaclisib With or Without Polatuzumab Vedotin Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma (NCT04323956)
    Phase 1
    Mayo Clinic
    Active, not recruiting
    Last update posted :
    10/30/2023
    Initiation :
    06/15/2020
    Primary completion :
    05/15/2026
    Completion :
    05/15/2027
    MYC • BCL2 • CD20 • BCL6
    |
    BCL2 expression • MYC expression • CD20 expression • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Truxima (rituximab-abbs) • parsaclisib (INCB50465) • Polivy (polatuzumab vedotin-piiq) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Neupogen (filgrastim) • Novex (rituximab biosimilar) • cyclophosphamide intravenous
    Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma (NCT04491370)
    Phase 1/2
    New York Medical College
    Recruiting
    Last update posted :
    10/26/2023
    Initiation :
    08/01/2021
    Primary completion :
    08/15/2024
    Completion :
    08/15/2025
    CD20 • CD34
    |
    Polivy (polatuzumab vedotin-piiq)
    POLA+BR for Relapsed or Refractory DLBCL (NCT04535102)
    Phase 2
    University of Colorado, Denver
    Withdrawn
    Last update posted :
    05/09/2022
    Initiation :
    01/29/2021
    Primary completion :
    03/17/2022
    Completion :
    03/17/2022
    MYC • BCL2 • BCL6
    |
    Rituxan (rituximab) • bendamustine • Polivy (polatuzumab vedotin-piiq)